Newswise — TAMPA, Fla., Dec. 11, 2023 /PRNewswire/ -- Amidst the demand for innovative dry eye solutions, a groundbreaking collaboration between distinguished scientists and healthcare experts has been published in an exceptional white paper revealing the questions surrounding Dry Eye Disease (DED). This pioneering scientific publication marks the genesis of a revolutionary approach to transforming dry eye treatment by uncovering the condition's fundamental causes. This paper introduces the topic of Tear Hyperosmolarity (THO) which is often responsible for the discomfort associated with dry, irritated eyes, ultimately leading to inflammation and damage to the eye. The Regener-Eyes® Founder and Chief Medical Officer, Dr. Carl Randall Harrell, along with contributing expert Dr. Lisa Feulner, unveil their latest research in the paper titled 'The Molecular Mechanisms Responsible for Tear Hyperosmolarity-Induced Pathological Changes in the Eyes of DED Patients,' aiming to demystify the complexities surrounding DED.
A central takeaway from this comprehensive paper is the identification of Tear Hyperosmolarity (THO). A central player in the development and progression of DED. Furthermore, this methodically curated paper presents viable solutions, such as tailored eye drops, to rebalance tear composition and bring relief to individuals suffering from dry eyes.
Increased prevalence in dry eye has fostered ongoing research, where scientists are dedicated to providing tangible solutions to enhance the comfort of those experiencing dry eyes.
In conclusion, these innovative specialists emphasize the significance of their findings and propose potential avenues for further exploration. They outline the promising impact of hypo-osmotic eye drops in mitigating THO-induced damage and suggest additional strategies, such as NF-κB inhibitors and combination options, for more effective DED treatment.
Quote:
"Innovative new research now reveals the complex interplay of molecular processes underlying dry eye disease. THO (Tear Hyperosmolarity) is specifically identified as a main culprit behind dry eye disease which can trigger inflammation and damage to the ocular immune system. This understanding has led to the development of Regener-Eyes Ophthalmic Solution, a Preservative Free hypo-osmotic eye drop, enriched with osmo-protectants.
These new findings, presented in a newly published white paper 'Molecular Mechanisms Responsible for Tear Hyperosmolarity,' open new avenues for treating dry eye disease. Understanding these mechanisms is a crucial step towards developing targeted therapies that can truly make a difference for individuals struggling with dry eyes."
- Dr. C. Randall Harrell, MD
Regenerative Processing Plant:
Regenerative Processing Plant is at the forefront of manufacturing innovative products such as Regener-Eyes® Ophthalmic Solution, dedicated to advancing treatments that enhance patients' well-being.
Link to white paper:
RSS